Skip to content
★ Sign in to follow
JC

Joanne Curley

Directeur du Développement
Total declarations
87
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (48 ops.)
€1.8M

Latest filing published 23 Aug 2023 for Vera Therapeutics, Inc., €23k.

Filing timeline

BuySale
Joanne Curley

Insider track record

Disclosed buys
0
Disclosed sells
48

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Joanne Curley: trading record in brief

Joanne Curley, listed as senior executive, appears in our data through filings on Vera Therapeutics, Inc. shares, published by SEC (Form 4). We count 87 filings; the first trade dates from 31 May 2022 and the latest from 21 August 2023.

On the market, this insider has only sold: 48 sales, €1.8M in total. Outside the open market, there are 1 share grant and 38 option exercises. In 2023 alone, the filings show no purchases and 1 sale.

The latest filing, published on 23 August 2023, reports an open-market sale of €23k in Vera Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Joanne Curley

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations18 total
  • ▼
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    24,817 USD41SEC
    1,490 shares@ US$16.65588.1% of flowClass A Common StockSEC:0001209191-23-047103:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    4,140 USD25SEC
    1,429 shares@ US$2.89681.4% of flowClass A Common StockSEC:0001209191-22-061973:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    75,900 USD28SEC
    6,900 shares@ US$11.0025.5% of flowClass A Common StockSEC:0001209191-22-061178:0
  • ▼
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    8,136 USD25SEC
    494 shares@ US$16.472.8% of flowClass A Common StockSEC:0001209191-22-060331:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    6,870 USD25SEC
    1,078 shares@ US$6.37282.3% of flowClass A Common StockSEC:0001209191-22-058095:0
  • ▼
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    8,171 USD25SEC
    494 shares@ US$16.542.9% of flowClass A Common StockSEC:0001209191-22-056364:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    6,870 USD25SEC
    1,078 shares@ US$6.37282.5% of flowClass A Common StockSEC:0001209191-22-054192:0
  • ▼
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    21,380 USD26SEC
    988 shares@ US$21.647.6% of flowClass A Common StockSEC:0001209191-22-052972:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    6,233 USD25SEC
    978 shares@ US$6.37282.2% of flowClass A Common StockSEC:0001209191-22-051002:0
  • ▼
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    18,406 USD26SEC
    988 shares@ US$18.636.5% of flowClass A Common StockSEC:0001209191-22-049176:0
  • ◆
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    0SEC
    12,500 shares0Class A Common StockSEC:0001209191-22-047172:0
  • ▼
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    16,608 USD26SEC
    988 shares@ US$16.815.8% of flowClass A Common StockSEC:0001209191-22-044412:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    34,311 USD26SEC
    5,384 shares@ US$6.372811.9% of flowClass A Common StockSEC:0001209191-22-042675:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    18,406 USD26SEC
    6,354 shares@ US$2.89686.5% of flowClass A Common StockSEC:0001209191-22-042255:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    22,222 USD26SEC
    3,487 shares@ US$6.37287.7% of flowClass A Common StockSEC:0001209191-22-041771:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    7,896 USD21SEC
    1,239 shares@ US$6.37280.0004% mcap41.6% of flowClass A Common StockSEC:0001209191-22-039055:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    8,578 USD22SEC
    1,346 shares@ US$6.37280.0004% mcap45.2% of flowClass A Common StockSEC:0001209191-22-038582:0
  • ◇
    Chief Development OfficerExecutivesVera Therapeutics, Inc.
    2,549 USD11SEC
    400 shares@ US$6.37280.8% of flowClass A Common StockSEC:0001209191-22-033485:0

18 of 18 declarations